TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing (NASDAQ:TGTX)

Group 1 - The core viewpoint is that TG Therapeutics (TGTX) has experienced softer sales growth for its product Briumvi in recent quarters, leading to a hold rating due to potential for a TV campaign to boost sales in the near term [1] Group 2 - The article emphasizes the importance of trading around significant events such as trial results and NDA/BLA approvals in the biotech sector [1]